https://www.selleckchem.com/pr....oducts/nvp-bgt226.ht
022), MMR at 12 months (P = 0.041) which essentially resulted in better 2-year FFS (p = 0.05). Also, patients who achieved EMR at 3 months, 6 months and MMR at 12 months had better FFS when compared to those who did not. This study suggests the incorporation of these variables in to the imatinib dosing algorithm as predictive biomarkers of response to Imatinib therapy.This article addresses an optimisation problem of distributing rapid diagnostic kits among patients when the demands far surpass the supplies. This problem has not been
Like
Comment
Share
